Nemluvio (nemolizumab-ilto) / Roche, Maruho, Galderma - LARVOL DELTA

Comparative disproportionality of adverse events across four type 2 inflammation-targeting biologics for atopic dermatitis: a FAERS analysis of dupilumab, tralokinumab, lebrikizumab, and nemolizumab (EADV 2026) - No abstract available

Adverse events • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Inflammation

Studies of Nemolizumab in the treatment of systemic sclerosis in adults. (clinicaltrials.gov) - P2 | N=16 | Not yet recruiting | Sponsor: Galderma SA / KeYi International Trading (Shanghai) Co., Ltd. / Vetter Pharma-Fertigung GmbH & Co. KG

New P2 trial • Immunology • Scleroderma • Systemic Sclerosis

Galderma and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for NEMLUVIO (nemolizumab), for moderate-to-severe atopic dermatitis and prurigo nodularis (PRNewswire)

Reimbursement • Atopic Dermatitis • Immunology • Prurigo Nodularis

Rapid Improvement of Refractory Pruritus in Extragenital and Perianal Lichen Sclerosus With Nemolizumab: A Case Report. (PubMed, Cureus) - "Prior treatments included betamethasone dipropionate 0.05% cream, intralesional triamcinolone acetonide, and office-based narrowband ultraviolet B phototherapy, the latter producing remission from 2021 until early 2026 before recurrence...No other topical, systemic, or phototherapy treatment was used after nemolizumab initiation through the first eight weeks...A short pulse of clobetasol 0.05% ointment was initiated for perianal disease at the eight-week visit while nemolizumab was continued. This case suggests that nemolizumab may provide rapid symptomatic relief of refractory pruritus associated with lichen sclerosus, even without early morphologic resolution."

Journal • Dermatology • Dermatopathology • Pruritus • IL31RA

EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences (Businesswire) - "Highlights include an oral presentation on the safety and efficacy data from the ARCADIA open-label long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis, at 152 weeks....Additional presentations will quantify the impact of itch and skin lesion severity on quality of life in atopic dermatitis and evaluate the long-term safety profile of Nemluvio over two years across the ARCADIA and OLYMPIA extension studies."

P3 data • Acne Vulgaris • Atopic Dermatitis • Immunology • Prurigo Nodularis

Comparative efficacy of upadacitinib and nemolizumab with background topical therapy in adults and adolescents with moderate-to-severe atopic dermatitis: a placebo-anchored matching-adjusted indirect comparison (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dupilumab Demonstrates a Significantly Higher Likelihood of Achieving Improvements in Atopic Dermatitis Signs and Itch vs Nemolizumab at Week 16 in Combination With Topical Corticosteroids: Results From a Bucher Placebo-Adjusted Indirect Comparison (EADV 2026) - No abstract available

Clinical • Combination therapy • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dramatic Improvement of Treatment-Refractory Prurigo Nodularis Following Initiation of Semaglutide: A Case Report. (PubMed, Clin Cosmet Investig Dermatol) - "Despite an expanding therapeutic armamentarium including dupilumab and nemolizumab, a subset of patients remains inadequately controlled...We report the case of a 64-year-old man with severe, treatment-refractory PN who had failed multiple lines of therapy over four years, including potent topical corticosteroids, dupilumab, and methotrexate...The potential mechanisms underlying this benefit include modulation of low-grade chronic inflammation, direct effects on GLP-1 receptor-expressing immune cells, possible modulation of Th2 immune response, and anti-nociceptive action on pruritus via central and peripheral neuro-immune pathways. This observation highlights the potential of GLP-1 RAs as adjunctive therapy in refractory inflammatory dermatoses and warrants further investigation."

Journal • Dermatology • Diabetes • Genetic Disorders • Immunology • Inflammation • Metabolic Disorders • Obesity • Prurigo Nodularis • Pruritus • Type 2 Diabetes Mellitus

Anchored matching-adjusted indirect comparison of the efficacy of dupilumab vs nemolizumab in patients with moderate-to-severe atopic dermatitis (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Dupilumab and nemolizumab for chronic pruritus in cancer patients under oncologic treatment – a multicentric retrospective study from the EADV Task Force dermatology for cancer patients (EADV 2026) - No abstract available

Retrospective data • Dermatology • Oncology • Pruritus

Treatment algorithm (EADV 2026) - "Topical and systemic anti-inflammatory and immunosuppressive therapies are still recommended or suggested in CPG, namely topical corticosteroids and calcineurin inhibitors, phototherapy (mostly nb-UVB), methotrexate and cyclosporin...In the last five years biologics inhibiting Th2 cytokines (IL-4/13 and IL-31), like dupilumab and nemolizumab, have been approved for the treatment of moderate to severe CPG due to their high efficacy and safety, independent of the atopic status and several other comorbidities...know available drugs to manage patients with CPG, their mechanism of action, efiicacy and safety 2. Understand how we can evaluate and adjust therapy"

Addiction (Opioid and Alcohol) • IL4

Nemolizumab for the treatment of pruritus in therapy-refractory CTCL: a case series from clinical practice (ADO 2026) - No abstract available

Clinical • Cutaneous T-cell Lymphoma • Dermatology • Pruritus

Development of a Conceptual Disease Model of Atopic Dermatitis Using Data from the Phase 3 ARCADIA 1 Trial. (PubMed, Dermatol Ther (Heidelb)) - P3 | "The CDM identifies itch severity as a central driver of the patient burden in moderate-to-severe AD and supports prioritization of itch and sleep disturbance in clinical assessment, therapeutic planning, and outcome evaluation in AD. Our model, whose validity is strengthened by expert consensus, can potentially guide clinical decision-making and evaluation of treatment responses across key domains of AD burden."

Journal • P3 data • Atopic Dermatitis • CNS Disorders • Dermatitis • Dermatology • Immunology • Pruritus • Sleep Disorder

Early pruritus reduction following nemolizumab in atopic dermatitis and prurigo nodularis patients: A Real-World Study (EADV 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis • Pruritus

Evolution of clinical response with long-term nemolizumab therapy in prurigo nodularis: From symptom relief to improvements in sleep and quality of life. (EADV 2026) - No abstract available

Clinical • HEOR • Immunology • Prurigo Nodularis

Comparative Durability Of Response After Biologic Withdrawal: A Systematic Review Of Icotrokinra, Nemolizumab, And Bimekizumab Rebound Data. Defining A New "Treatment-Free Remission Probability Score" (EADV 2026) - No abstract available

Clinical • Review

Nemolizumab in prurigo nodularis: real-world efficacy and comorbidity profile - a single-centre experience (EADV 2026) - No abstract available

Clinical • Real-world • Real-world effectiveness • Real-world evidence • Immunology • Prurigo Nodularis

Long-term safety profile of nemolizumab over 2 years in moderate-to-severe atopic dermatitis and prurigo nodularis: Post hoc analysis from ARCADIA LTE and OLYMPIA LTE trials (EADV 2026) - No abstract available

Clinical • Retrospective data • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis

Nemolizumab in dominant dystrophic epidermolysis bullosa pruriginosa (EADV 2026) - No abstract available

Dermatology

nemolizumab in post burn pruritus : a case series (EADV 2026) - No abstract available

Clinical • Dermatology • Pruritus

Lichenoid and Interface Dermatitis Rapidly Cleared with Nemolizumab: A Case Report (EADV 2026) - No abstract available

Case report • Clinical • Dermatitis • Dermatology • Immunology

Long-term safety and efficacy (up to 152 weeks) of nemolizumab in ARCADIA open-label long-term extension study in adults and adolescents with moderate-to-severe atopic dermatitis. (EADV 2026) - No abstract available

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

Interleukin-31 in Atopic Dermatitis and Prurigo Nodularis: Pathophysiology, Neuroimmune Mechanisms, and Clinical Efficacy of Nemolizumab. (PubMed, J Drugs Dermatol) - "Beyond these neuroimmune effects, IL-31 disrupts epidermal barrier integrity and acts directly on dermal fibroblasts to drive collagen synthesis and extracellular matrix remodeling, contributing to the lichenification of chronic AD and the hyperkeratotic nodule formation that defines PN. This narrative review integrates the mechanistic biology of IL-31 across both conditions with the clinical evidence base for nemolizumab, a humanized monoclonal antibody targeting IL-31RA, examining phase 3 trial data, long-term extension outcomes, translational biomarker evidence, and emerging real-world experience."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Prurigo Nodularis • CD123 • IL13 • IL31RA • IL4 • OSMR

RANDOMIZED CONTROLLED STUDY OF NEMOLIZUMAB IN PATIENTS WITH CHRONIC KIDNEY DISEASE AND ASSOCIATED PRURITUS: NIKAIA-1. (PubMed, J Am Acad Dermatol) - "Although the primary endpoint was not met, the trial demonstrated a favorable safety profile and signals of reduced pruritus and improved itch-related QoL in patients with CKD-aP over 12 weeks."

Journal • Chronic Kidney Disease • CNS Disorders • Dermatitis • Dermatology • Immunology • Nephrology • Prurigo Nodularis • Pruritus • Renal Disease • Sleep Disorder

Tape Strip Transcriptomics Reveal Nemolizumab Effects on Pruritus, Hyperplasia, Inflammation, and Extracellular Matrix Markers in Patients With Moderate-to-Severe Atopic Dermatitis. (PubMed, Allergy) - P3 | "Our findings provide molecular evidence supporting nemolizumab's therapeutic efficacy across multiple disease domains, including pruritus, inflammation, and epidermal hyperplasia, highlighting its role in AD treatment and management."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Fibrosis • Immunology • Inflammation • Pruritus • COL1A1 • IGFBP3 • KLK6 • MX1 • OASL • OSMR